Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
NEW YORK, Sept. 07, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Insmed Incorporated (“Insmed” or the “Company”) (NASDAQ:INSM) between March 18, 2013 and June 8, 2016.
You are hereby notified that a securities class action has commenced in the USDC for the District of New Jersey. If you purchased or otherwise acquired Insmed securities between March 18, 2013 and June 8, 2016, your rights may be affected by this action. To get more information go to: http://www.zlk.com/pslra/insmed-incorporated.
The complaint alleges that, throughout the Class Period, defendants issued false and misleading statements to investors and/or failed to disclose that: (1) the data supporting Insmed’s European marketing authorization application (“MAA”) for lead product candidate ARIKAYCE was not likely to be approved by the European Medicines Agency (“EMA”) for the treatment of NTM lung disease, and (2) therefore ARIKAYCE’S approval by the EMA and subsequent commercialization in Europe were less likely and/or imminent than Insmed led investors to believe.
On June 8, 2016, Insmed announced it had withdrawn its MAA for ARIKAYCE from the EMA, revealing that the Committee for Medicinal Products for Human Use indicated that the phase 2 study did not provide a sufficient amount of evidence to support an approval.
If you suffered a loss in Insmed you have until September 13, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://www.zlk.com/pslra/insmed-incorporated.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
